Canalevia_Logo.png
  • VETERINARY PROFESSIONALS
  • ORDER NOW
  • EVENTS
  • DOG OWNERS
  • ABOUT US
  • MEDIA MENTIONS
Jaguar Animal Health
  • Oct 31
2022

Jaguar Animal Health Sponsors October 26th Episode of dvm360 Live!...

Jaguar Animal Health
  • Jun 20
2022

Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine..

Jaguar Animal Health
  • Apr 26
2022

Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer)...

Jaguar Animal Health
  • Apr 5
2022

Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About...

Jaguar Animal Health
  • Feb 27
2022

Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea..

Jaguar Animal Health
  • Feb 13
2022

Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of...

Jaguar Animal Health
  • Jan 11
2022

Jaguar Animal Health to Host Chemotherapy-Induced Diarrhea Treatment Forum for Veterinarians at VMX

Jaguar Animal Health
  • Jan 4
2022

Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of...

Jaguar Animal Health
  • Jan 3
2022

Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced...

Contact Us

 

1 (877) 787-3001

info@canalevia.com

  • Instagram
  • Facebook
  • LinkedIn

Location

 

Jaguar Animal Health

200 Pine Street, Suite 600

San Francisco, CA 94104

Home

Resources

Events

About Us

Join Our Mailing List

Investor Relations

Partnering with Canalevia-CA1

Canalevia_byJAG_Logo_White.png

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.

​

IMPORTANT SAFETY INFORMATION

For oral use in dogs only. Not for use in humans. Keep Canalevia®-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.